RSS   Newsletter   Contact   Advertise with us

Pharma companies invested half a trillion dollars in new drugs

Share on Twitter Share on LinkedIn
Staff writer ▼ | October 26, 2015
While government research supports basic research, America's biopharmaceutical companies conduct the critical R&D needed to bring new medicines to patients and bear the associated costs and risks.
Pharma companies
Research   7,000 new medicines are being developed
In fact, the biopharmaceutical sector spends more on R&D than the entire National Institutes of Health operating budget with PhRMA member companies investing $51.2 billion in 2014, and over half a trillion dollars since 2000, according to PhRMA, the Pharmaceutical Research and Manufacturers of America.

This amount represents about one in every five dollars spent on domestic R&D by U.S. businesses. The investment not only fosters medicines through the long and complex development process, but also supports a total of about 3.4 million jobs across the country, including approximately 810,000 direct jobs.

In a recent white paper from the Tufts University School of Medicine, the authors found that in "two decades of reliable analyses by academia and government, assessed using a variety of methodological approaches, consistently demonstrate that 67 percent to 97 percent of drug development is conducted by the private sector."

The paper went on to say that, "While the basic science underpinning the key disciplines needed to discover and develop drugs is often initiated in academia, it is primarily the biopharmaceutical industry where the crucial disciplines of medicinal chemistry, process chemistry and formulation, drug metabolism and pharmacokinetics, and safety sciences are practiced at a scale and level of integration necessary in order to bring a new medicine to the patients that need them."

As a result of past and current investments, the pipeline of new and innovative medicines has never been more promising and patients are benefiting.

Today, 7,000 new medicines are being developed around the world and 70 percent of new medicines in development are potential first-in-class therapies, meaning they use a completely new approach to fighting a disease.

And as more and more therapies become tailored to individuals, 42 percent of new medicines in the pipeline have the potential to be personalized medicines.

All of these advancements occur even though biopharmaceutical R&D is an extremely complex process and failures are more common than success. In fact, just 12 percent of drugs entering clinical trials ever make it to patients and thousands won't even reach past the early discovery and pre-clinical testing stages.

Furthermore, to bring one medicine to market alone costs the biopharmaceutical industry on average of $2.6 billion – including failure and often takes 10-15 years.

America's biopharmaceutical research companies' sole focus will continue to be developing innovative, lifesaving medicines to help patients live longer, healthier lives. To learn more about the process behind bringing new treatments to patients, visit Innovation.org.

POST Online Media Contact